- Paige — a leader in computational pathology — announced that it raised an additional $15 million from Goldman Sachs Merchant Banking Division
Paige — a leader in computational pathology — announced that it raised an additional $15 million from Goldman Sachs Merchant Banking Division. This totals $20 million from Goldman Sachs.
This round of funding will be added to the previously announced Series B financing, which brings the total round to $70 million — including an additional investment from Healthcare Venture Partners of $5 million on top of their previous $10 million investment.
This round of funding brings the company’s total capital raised to more than $95 million. And Paige will use this new capital to further accelerate its global leadership position in transforming pathology workflows in the field of cancer while working closely with biopharma companies to create custom diagnostic and clinical trial solutions to improve patient care.
One of the recent company milestones for Paige includes naming David Castelblanco, Managing Director at Goldman Sachs, as a new member to Paige’s Board of Directors.
Key Quotes:
“We appreciate the continued recognition and support we’ve received from Goldman Sachs as we gain traction and prove early results in the clinical and biopharma space. This new funding will help ensure that the Paige Platform and our advanced computational pathology products will drive the next generation of pathology and improve cancer care globally.”
— Leo Grady, Ph.D., CEO of Paige
“We have been very impressed with the Company and its pace of development. We are excited to increase our commitment to support Leo, Thomas and the Paige team’s transformative work with artificial intelligence and machine learning in the cancer field.”
— David Castelblanco.
“We initially invested in Paige recognizing the potential of their products to add significant value to the industry and impact the future of cancer care. After seeing Paige make tremendous progress in such a short period, we added to our investment to further accelerate their growth.”
— Jeffrey C. Lightcap, Senior Managing Director of Healthcare Venture Partners
